France has now enacted a right to assisted dying, but the headline hides the question that matters to patients, families and lawyers across Europe: can a person living abroad travel to France and ask for the procedure? The answer is narrower than a promise of medical tourism. Law No. 2026-794 of 18 August 2026, enacted after the Constitutional Council’s Decision No. 2026-910 DC of 14 August, requires the applicant to be at least eighteen and either French or a person who resides stably and lawfully in France. A foreign patient cannot replace that condition with a flight ticket, a short hotel stay or a remote appointment. The statute also imposes a medical eligibility test, a formal request, a multidisciplinary review, a waiting period, a controlled pharmacy route and a right to challenge the doctor’s decision before the administrative courts. This is a fast-moving cross-border issue because the new French framework sits beside European patient-mobility rules, foreign medical records, residence documents, insurance contracts and possible disputes about access. The analysis below explains what the new law does, what it does not do, and how a foreign family should prepare a legally credible file before contacting a French doctor.
I. Can a foreign patient qualify under France’s 2026 assisted-dying law?
A. What did the Constitutional Council actually validate?
The news is new, but the legal answer is already anchored in an enacted statute. The official text of Law No. 2026-794 of 18 August 2026 was published in the Journal officiel after the Constitutional Council reviewed the legislation. The statute inserts a new section in the French Public Health Code and calls the mechanism a right to assisted dying. It covers both situations in which the person takes the lethal substance herself and the limited situation in which a doctor or nurse administers it because the person is not physically able to do so. That distinction is not cosmetic. The statutory safeguards, the professional role and the criminal protection depend on the procedure being followed exactly.
The Constitutional Council’s Decision No. 2026-910 DC of 14 August 2026 did not create an unlimited constitutional entitlement to die in France. It reviewed the conditions chosen by Parliament and upheld the central framework, subject to reservations on particular safeguards. The Council expressly considered the age and nationality-or-residence conditions in Article L. 1111-12-2 of the Public Health Code. It also treated the new criminal protection as conditional: a person who participates in the procedure benefits from the statutory protection only when the applicant’s right has been exercised under the rules governing the request, review and administration.
The first answer for a foreign patient is therefore found in Article L. 1111-12-2 of the French Public Health Code, created by Article 4 of the law. The second condition is quoted here exactly: Etre de nationalité française ou résider de façon stable et régulière en France
. The statute uses an alternative, not a cumulative test. A French national living outside France may rely on nationality, subject to all the other requirements. A non-French national must show stable and regular residence in France. Nothing in this wording says that an EU passport, private insurance, a French address for correspondence or the purchase of treatment is enough by itself.
The phrase “stable and regular residence” is the point at which many international enquiries will fail if they are treated as travel arrangements rather than legal files. The statute states the eligibility condition but does not set out, in the provision itself, a simple number of days that automatically proves stability. That does not mean that any short stay qualifies. It means that residence will require evidence assessed under the procedure and the implementing rules: immigration status, continuity of presence, an established personal or family life, administrative records, health-care registration where relevant and the real connection between the person and France. The future regulatory framework may specify forms and verification methods, but it cannot be replaced by a marketing assertion that a patient can become eligible by arriving shortly before the request.
The distinction between a French national abroad and a foreign national abroad matters. A French citizen who receives treatment in another country may still satisfy the nationality limb, although the medical and procedural questions remain French questions. A British, American, Canadian, Swiss or other non-French citizen who has no stable and lawful French residence cannot rely on the French nationality limb. A European citizen’s freedom to move does not automatically convert a short stay into stable residence. The legal file must establish eligibility before the doctor can lawfully proceed; a cross-border family should therefore collect residence evidence before attempting to solve the medical question.
The medical conditions are cumulative. The applicant must be an adult, have a serious and incurable condition of any cause that places life expectancy at risk and is in an advanced or terminal phase, experience suffering connected with that condition that is either refractory to treatment or unbearable after the person chose not to receive or to stop treatment, and be able to express a free and informed decision. A psychological condition alone cannot satisfy the statutory suffering requirement. These are not broad compassion criteria that can be supplied by a general practitioner’s letter from abroad. They require a clinical assessment within the French procedure, supported by reliable medical material.
The new right also sits alongside the existing French law on refusal of treatment and palliative care. In Constitutional Council Decision No. 2017-632 QPC of 2 June 2017, the Court examined provisions allowing treatment to be stopped when it reflected unreasonable obstinacy. The decision reproduced the rule that Les actes mentionnés à l’article L. 1110-5 ne doivent pas être mis en œuvre ou poursuivis lorsqu’ils résultent d’une obstination déraisonnable
. That is a different legal pathway. Refusing disproportionate treatment or receiving palliative care is not the same as requesting a lethal substance under the new Articles L. 1111-12-1 to L. 1111-12-13.
The distinction is also visible in Conseil d’État, 1st–6th Chambers, 6 December 2017, No. 403944, which concerned the procedure for limiting or stopping treatment for a patient unable to express a will. The judgment held that the medical decision must follow a collegial process and preserve access to an effective legal remedy. It concerned treatment withdrawal and continuous deep sedation, not a right for a non-resident to seek assisted dying. International families should not cite the Lambert litigation or the earlier end-of-life jurisprudence as if it had already answered eligibility under the 2026 statute.
The European Court of Human Rights reached a related but carefully limited conclusion in Lambert and Others v. France, Grand Chamber, application No. 46043/14, 5 June 2015. The case concerned the withdrawal of artificial nutrition and hydration and the procedural safeguards surrounding that decision. It confirmed that end-of-life law involves difficult questions on which States retain a margin of appreciation. It did not order France to open a cross-border assisted-dying service, and it did not transform Article 2 of the European Convention into a right to obtain a lethal substance in another State. The new French statute must be read on its own terms.
Finally, the law is not a promise that every eligible person can obtain the procedure immediately. Article L. 1111-12-11 of the Public Health Code sends important implementation questions to a Conseil d’État decree, including the information given to the applicant, the form of the request and confirmation, the procedure for verifying the eligibility conditions and access to a register concerning legal protection. The Constitutional Council accepted that delegation because the law itself defines the essential safeguards. For a foreign patient, the practical message is to distinguish the enacted right from the administrative machinery required to make a request operational.
B. Why does the residence rule block simple medical tourism?
The phrase “medical tourism” is useful only if it is used carefully. France’s new law does not create an open international service for people who choose the country because another jurisdiction has refused their request. A person who enters France for a short medical visit may receive ordinary care under the rules that apply to that care, but the assisted-dying statute adds a personal eligibility condition. A hotel booking proves a place to sleep. It does not prove stable and regular residence. A private hospital invoice proves a financial relationship. It does not prove the statutory connection to France.
That condition is compatible with the way European patient mobility is normally organised. Directive 2011/24/EU on patients’ rights in cross-border healthcare facilitates access to safe and high-quality care while expressly preserving national competence. Its Article 1 says the system operates in “full respect of national competencies in organising and delivering healthcare.” The Directive can regulate information, reimbursement, prescriptions and cooperation. It does not harmonise every substantive medical eligibility rule, and it does not prevent a Member State from defining who may access a procedure that its legislature has created.
The Directive’s own recitals are even more direct about travel. It does not give a person an entitlement to enter, stay or reside in a Member State in order to receive healthcare. That principle matters to the French residence requirement. An EU patient may have rights to seek certain healthcare across a border, but those rights do not automatically create a right to establish the residence needed for a separate end-of-life procedure. The patient’s nationality, immigration position, residence and medical eligibility must be kept as distinct questions.
A foreign patient may nevertheless qualify. The statute does not say that the patient must have been born in France, hold French health insurance or have French citizenship. A non-French national who genuinely resides in France in a stable and lawful way may satisfy the second limb, subject to the other four conditions. That can cover a long-term resident, a person with a durable family or professional life in France, or another person whose status and factual connection meet the legal test. The statute does not provide a shortcut for a person who merely wants to avoid a refusal in the country where she normally lives.
The evidence should be assembled before the first formal request. A foreign applicant should consider the residence permit or EU registration documents, tax or social records where appropriate, rental or ownership evidence, utility history, employment or family documents, French medical registration, and proof of continuous lawful presence. No single document decides the question. The aim is to show a real and stable connection rather than to manufacture an address. A doctor should also receive a translated and chronologically organised medical record, with the original documents preserved and the translator’s qualifications recorded.
Medical translation is not an administrative afterthought. The French doctor must explain the condition, prognosis, treatment alternatives, palliative care and the assisted-dying procedure in a way that allows a free and informed choice. A foreign report may use a different classification of disease, a different concept of terminal phase or a different approach to intolerable suffering. The applicant and counsel should identify those differences before the collegial assessment. A literal translation of the diagnosis will not always explain the clinical meaning that the French procedure requires.
Remote contact also has a statutory limit. Article L. 1111-12-3 of the Public Health Code provides that the request is made to an active doctor who is not a relative or another person excluded by the provision. The text states exactly: La personne ne peut ni présenter ni confirmer sa demande lors d’une téléconsultation.
If the patient cannot physically travel, the doctor must attend the person at home or at the place where care is provided. That rule does not prohibit an initial telephone enquiry or the secure transfer of records. It does mean that a foreign patient cannot complete the formal request and confirmation entirely through a video platform.
The same rule protects the quality of the decision. The applicant must be seen in a setting in which the doctor can assess capacity, pressure, physical inability and the reliability of the request. A lawyer or family member may help organise information, but cannot replace the applicant’s own free and informed expression. Any document suggesting that a relative, broker, clinic or charity is directing the choice should be examined immediately. The law is designed to prevent a vulnerable person from being converted into a cross-border transaction.
There is also a timing risk. Parliament required a medical decision after a collegial process, a minimum two-day reflection period before confirmation and a renewed assessment if the administration date is delayed beyond three months from notification of the decision. The law therefore does not support a “weekend in Paris” model. Even an eligible resident may need time for the first consultation, independent medical review, translation, the collegial meeting, the decision, confirmation, pharmacy preparation and the final check on the day. Immigration, accommodation, family travel and insurance must be planned around that legal sequence.
Cross-border families must also resist the temptation to treat a refusal as proof of discrimination. A French doctor may refuse if a condition is not met, if the evidence is insufficient, if the request is not free and informed or if the residence requirement is not established. The decision must be analysed against the statute and the record. A nationality-based refusal that simply ignores a lawful stable residence may raise a different question from a refusal because the applicant has no French residence. A carefully prepared administrative challenge will need the exact reason, the supporting documents and the date of notification.
II. What should foreign families, doctors and lawyers do next?
A. How should the request and any urgent challenge be prepared?
The first practical step is to separate the file into four folders: identity and residence, medical evidence, the applicant’s own wishes, and procedure. The identity folder should answer who the patient is and why the French nationality-or-residence condition is satisfied. The medical folder should explain the diagnosis, the stage of the condition, treatment history, pain or suffering, palliative options and the views of the treating doctors. The wishes folder should preserve advance statements and direct expressions without allowing a family narrative to replace the patient’s voice. The procedure folder should record every request, consent, refusal, appointment, notification and deadline.
The formal application begins with a doctor who meets the statutory independence requirements. Article L. 1111-12-3 requires the doctor to explain the state of health, its prospects, available treatments and support, and the possibility of palliative care. The doctor must also explain the assisted-dying conditions and how the procedure works. Only after those explanations does the patient formalise the request in writing or, where necessary, through another mode adapted to her capacities. The foreign patient should not sign a pre-drafted request prepared by a travel agent, clinic or relative without an independent explanation and an opportunity to withdraw.
The eligibility assessment is not a single doctor’s informal opinion. Article L. 1111-12-4 of the Public Health Code requires a collegial process for the medical conditions, with the requesting doctor and other professionals. The doctor must verify the conditions, gather the necessary medical information and decide at the end of the process. The decision is notified orally and in writing, with reasons, within fifteen days after the request is formalised. The patient may confirm after a reflection period of at least two days. If more than three months pass, the doctor must reassess the free and informed nature of the decision and may need to repeat elements of the process.
A foreign report can be evidence, but it does not remove the French doctor’s responsibility. The doctor must decide whether the medical condition meets the statutory language, not simply repeat the conclusion of a foreign certificate. Counsel should create a table matching each legal condition to the document that supports it and to any document that creates doubt. If a report says “terminal” under a foreign law but describes a condition that is not in an advanced or terminal phase under the French text, the discrepancy should be addressed openly. Concealing it can damage both the request and any later court challenge.
The law requires the multidisciplinary college to meet physically, although it can use videoconference or telecommunications if physical attendance is impossible. Foreign participants may need an interpreter, secure medical transmission and consent for the sharing of records. The patient’s privacy and professional secrecy remain important, but an applicant cannot demand a decision while refusing every medical document necessary to verify the statutory conditions. The practical balance is a limited, documented disclosure to the professionals taking part in the legal procedure, with a clear record of who received each document.
The choice of place comes later. Article L. 1111-12-5 allows the person to determine the place of administration in agreement with the doctor or nurse. It can be the person’s home or residence, the home of a relative, a health-care institution, a social or medico-social facility, or another structure where health professionals work. That flexibility helps a resident whose medical condition makes travel difficult. It does not erase the eligibility condition or turn a temporary accommodation into proof of stable residence. The place of administration and the legal connection to France are separate issues.
The pharmacy route makes the cross-border nature of the process even clearer. Under Article L. 1111-12-6, the lethal preparation follows a designated internal pharmacy or an agreed community pharmacy route. It is not a prescription that a patient can take to a foreign pharmacy or carry across a border as an ordinary medicine. The preparation is handled inside the French procedure, with a fixed administration date, a named professional and duties to return and destroy unused material. A family should not arrange parallel importation, courier delivery or storage abroad.
On the day itself, the patient must confirm the wish to proceed. Article L. 1111-12-7 requires the accompanying doctor or nurse to verify that confirmation and to stop or suspend the procedure if the person refuses, requests a postponement or is subjected to pressure. The professional must remain in the same room after administration so that the person can be assisted if necessary. For a foreign family, this means that travel arrangements, interpretation and family attendance must never be allowed to become pressure to continue. The request can be withdrawn at any time before administration.
The new law gives the applicant a specific route to court. Article L. 1111-12-10 provides that a doctor’s decision on the request, or a decision ending the procedure, may be challenged by the applicant before the administrative courts, including by an urgent liberty application. The statute says the challenge is brought devant la juridiction administrative
. A person responsible for a legal-protection measure may challenge an authorisation concerning a protected adult within two days of notification, and that challenge suspends the procedure in the circumstances stated by the law.
This allocation of jurisdiction is significant. The Constitutional Council held in Decision No. 2026-910 DC that the legislature could concentrate this dispute in the administrative courts even when the doctor works in a private setting. The court must assess the legality of the decision against the statutory conditions. The applicant therefore needs a precise record of the request, the medical reasons, the residence evidence, the notification and the date at which the administration is planned. An urgent application cannot be built from general disagreement with the law; it must identify the legal error, the serious and immediate consequence, and the evidence that the court can verify.
The earlier end-of-life cases help explain why timing matters. In Cour de cassation, First Civil Chamber, appeal No. 16-20.298, 8 December 2016, the Court dealt with litigation connected with the Lambert family and the representation of a patient in a dispute over treatment. That decision is part of the domestic history of French end-of-life litigation; it should not be cited as if it established the new assisted-dying right. The more direct procedural guidance comes from Conseil d’État No. 403944 and Constitutional Council Decision No. 2017-632 QPC: legal safeguards must be real, the medical process must be reasoned and an effective remedy must be available in time.
Representation from abroad should be organised early. A foreign patient may need a French lawyer to analyse residence, obtain medical records, arrange a certified translation, communicate with the doctor and prepare an urgent application. The lawyer cannot decide for the patient, certify a medical condition or manufacture a residence connection. The lawyer’s role is to translate facts into legal conditions, protect confidentiality, challenge an unlawful refusal and prevent a family member or commercial intermediary from taking control of a decision that belongs personally to the applicant.
B. How do EU mobility, insurance and cross-border disputes interact?
EU law creates opportunities for cooperation but does not supply a shortcut around French eligibility. Directive 2011/24/EU can help a patient obtain information about French providers, understand reimbursement rules and manage the movement of ordinary medical records or medicines. It also requires treatment in the Member State of treatment to follow that State’s law and quality rules. It does not harmonise assisted dying, and the Directive’s recital on entry and residence prevents it from being used as an immigration entitlement. An EU national who wants to apply in France should therefore ask two separate questions: what patient-mobility rights apply to the medical support, and does the French person-based statute permit the assisted-dying procedure?
Reimbursement is another trap. France’s new law modifies social-security and insurance provisions for the procedure, but a foreign patient’s home insurer is not automatically required to pay. The European cross-border healthcare rules generally concern reimbursement by the Member State of affiliation under their conditions. They do not mean that a home insurer must reimburse a procedure that its national law does not cover, and they do not turn a French eligibility refusal into a reimbursement dispute. Before travel, the patient should obtain a written position from the home insurer, the French provider and, where relevant, the national contact point for cross-border healthcare.
Life insurance and succession documents also require review. The statute provides that death insurance covers a death resulting from the assisted-dying procedure, including contracts in force when the new rule applies. That French rule may prevent the procedure from being treated as an automatic exclusion under a French contract, but it does not answer the law governing a foreign policy, a group policy issued in another State or a succession dispute involving several countries. The insurer should be asked about the governing law, beneficiary designation, disclosure obligations and any cross-border notification requirement. Families should preserve the policy, premium history and correspondence rather than rely on a verbal assurance.
The foreign patient’s immigration status can become urgent if the condition deteriorates while the residence evidence is still being assembled. A lawyer should not suggest an artificial change of address or a last-minute application for a status that has no factual basis. Instead, the file should explain the lawful residence already established and identify any pending administrative renewal. If the person has French nationality, the nationality document may avoid the residence dispute, but the medical procedure and the other eligibility conditions still apply. If the person is not French, the residence issue should be addressed before the medical timetable becomes impossible.
The status of the facility and professionals may also affect the date and location. Article L. 1111-12-12 creates an individual conscience clause and requires a professional who refuses to participate to give the applicant the name of professionals willing to participate. The Constitutional Council’s decision added an important operational reservation: pharmacists in the relevant pharmacies cannot be forced to participate, even though the law creates the preparation route. The Council also held that a private institution may refuse to host the procedure when it is manifestly contrary to its statutory missions or project, but only where other facilities can meet local needs. The applicant should obtain confirmation of the doctor, nurse, pharmacy and facility before fixing travel or family plans.
That reservation is not a licence for a facility to leave the patient without information. The statutory model seeks to preserve individual conscience and the practical availability of the right at the same time. For a foreign family, the correct response to a refusal is a documented referral and a check for an alternative professional or facility, not an accusation that France has denied the right altogether. If no lawful route remains, the applicant can assess the administrative and constitutional arguments with counsel. But the first remedy is often an accurate map of who is willing and authorised to participate.
Data and confidentiality become transnational issues as well. The law creates a system in which acts and strictly necessary information are recorded at each stage, and a commission checks procedures after the event. Foreign medical records, translated documents, identity information and legal-protection data may be transferred to professionals or institutions in France. The patient should know who is receiving which data, for what stage of the procedure and under what professional or statutory duty. A family should not circulate the full medical file through unsecured email, a public cloud folder or a travel broker. Counsel can create a restricted index and transmit only the records needed for the specific question.
There is a further international-law boundary. A foreign doctor cannot simply authorise the French procedure from abroad, and a French doctor cannot assume that a substance or act carried out outside France is governed only by French law. The location of the decision, the professional, the patient, the pharmacy, the administration and the death certificate may trigger different rules. If a patient is moved across a border after the French doctor has made a decision, that movement may change the legal and medical setting and must be reviewed before it occurs. The safest approach is to treat the French procedure as a connected chain and seek advice before breaking the chain.
Discrimination and equal-treatment claims must also be framed accurately. The nationality-or-residence condition treats French nationals and stable lawful residents differently from short-term visitors, but that distinction is written into the statute and was reviewed by the Constitutional Council. A challenge is more likely to focus on the interpretation or application of the residence condition, an unexplained refusal to consider evidence, a procedural defect, a failure to give reasons or a failure to provide the referral required by the conscience clause. The applicant should state which legal guarantee was breached and why the facts satisfy it. A general claim that every foreign patient has a human-rights entitlement to the procedure is unlikely to answer the actual French text.
Finally, the family should plan for what happens if the request is rejected. Preserve the full written decision, the date of notification and the evidence filed. Ask whether the doctor ended the procedure because an eligibility condition was absent, because the patient withdrew, because the evidence was incomplete or because a professional or facility refused to participate. Those reasons lead to different legal and practical responses. A fresh request may be possible in some circumstances, but it must follow the statutory process; an urgent administrative application may be available in others. The difference cannot be assessed from a short email saying “not eligible.”
Conclusion
France’s new assisted-dying law is a major legal development with an international edge, but it is not an invitation to travel to Paris for a procedure unavailable at home. A French national may satisfy the nationality condition even while living abroad. A non-French national must show stable and regular residence in France, in addition to adulthood, a serious and incurable condition in an advanced or terminal phase, qualifying suffering and a free and informed capacity to decide. A short stay, a hotel address, private insurance or a remote video consultation does not replace that legal test.
The procedure is equally important. A French doctor must receive the formal request, verify the evidence through a collegial process, give a reasoned decision, respect the reflection period, use the controlled pharmacy route and check the patient’s wishes on the day. A professional may invoke an individual conscience clause, while the Constitutional Council has protected pharmacists and allowed narrowly defined refusals by private facilities. The applicant can challenge the doctor’s decision in the administrative courts, including through urgent proceedings, but the success of that challenge will depend on a precise record.
For a foreign family, the sensible first move is a cross-border eligibility audit: nationality or residence, immigration documents, translated medical evidence, patient autonomy, insurance, the willing professionals and the possible court route. That preparation prevents the most damaging mistake—confusing European mobility or a compassionate public debate with an automatic legal entitlement. France has opened a tightly regulated right. Whether a particular foreign patient can use it will turn on the facts, the documents and the safeguards written into the French statute.